Comparison · NCT02545907-de66b39b
Dose Level 0- Safety Population vs Dose Level 1- Safety Population: Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dose Level 0- Safety Population vs Dose Level 1- Safety Population: Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0. Trial comparisons, record NCT02545907-de66b39b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02545907-de66b39b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.667 | 0.208 | 0.939 | wilson | |
| Risk in group 2 | 0.429 | 0.158 | 0.75 | wilson | |
| Risk difference, group 1 minus group 2 | 0.238 | -0.322 | 0.621 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.56 | 0.482 | 5.02 | log | |
| Odds ratio, group 1 over group 2 | 2.67 | 0.158 | 45.1 | log | |
| Number needed to treat, for one more participant with the outcome on Dose Level 0- Safety Population than on Dose Level 1- Safety Population | 4.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dose Level 0- Safety Population | All patients allocated to dose level 0 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set. | 2 | 3 | OG000 |
| Group 2 | Dose Level 1- Safety Population | All patients allocated to dose level 1 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set. | 3 | 7 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0.
- Description
- The percentage of patients treated who experience any grade 3 or 4 toxicity as assessed by CTCAE v4.0 throughout all treatment cycles will be assessed based on reported data.
- Time frame
- Between informed consent provided and 30 days post last trial treatment administration, up to 7 months
- Population
- All patients that receive at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set.
Source ClinicalTrials.gov
Trial
- Title
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- NCT number
- NCT02545907
- Phases
- PHASE1, PHASE2
- Conditions
- Amyloidosis
- Interventions
- Carfilzomib, Thalidomide, Dexamethasone
- Lead sponsor
- University College, London
- Results first posted
- 2021-04-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02545907?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02545907-de66b39b